Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage

Clinical Neuropharmacology

Volumn 30, Issue 2, 2007, Pages 72-85

  Tanner, Caroline ^a   Comella, Cynthia ^a,b   Kamp, Cornelia ^a   Kieburtz, Karl ^a,c   Oakes, David ^a,c   Marshall, Frederick ^a,c   Day, Denni ^a,c   Carter, Julie ^a,d   Pahwa, Rajesh ^a,e   Shoulson, Ira ^a,c   Truong, Daniel ^a,f   Tran, An Hao ^a,f   Thompson, Karen ^a,f   Shulman, Lisa M ^a,g   Rodriguez, Dinorah ^a,g   Fernandez, Mariella ^a,g   Ramos, Carmen Serrano ^a,h   Cruz, Adelma Rivera ^a,h   Petzinger, Giselle ^a   Everett, Sheila ^a   Rao, Jayaraman ^a,i   Das, Clare ^a,i   Sethi, Kapil ^a,j   Ligon, Kathy ^a,j   Waters, Cheryl ^a,k   Welsh, Mickie ^a,k   Feigin, Andrew ^a,l   Perlmutter, Joel ^a,m   McGee Minnich, Lori ^a,m   Marek, Kenneth ^a,n   Broshjeit, Susan ^a,n   Cellar, Janet ^a,n   Hurtig, Howard ^a,o   Matthews, Mary ^a,o   Shannon, Kathleen ^a,b   Janko, Kimberly ^a,b   Paulson, George ^a,p   Weeks, Carolyn ^a,p   Reider, Carson ^a,p   Trosch, Richard ^a,q   Mistura, Kathie ^a,q   Koller, William ^a,e   Evatt, Marian ^a,r   Wood, Colleen ^a,r   Pfeiffer, Ronald ^a,s   Rast, Sara ^a,s   Pfeiffer, Brenda ^a,s   Brocht, Alicia ^a,c   Casaceli, Cindy ^a,c   Freimuth, Andrea ^a,c   Hodgeman, Karen ^a,c   Watts, Arthur ^a,c   Goldman, Sam ^a   more..

^a PARKINSON S INSTITUTE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f Parkinson's and Movement Disorder Institute   (United States)

^g UNIVERSITY OF MIAMI   (United States)

^h UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

ⁱ LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^j MEDICAL COLLEGE OF GEORGIA   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^m WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ YALE UNIVERSITY   (United States)

^o PENNSYLVANIA HOSPITAL   (United States)

^p OHIO STATE UNIVERSITY   (United States)

^q Clinical Neuroscience Center   (United States)

^r EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

more..

Author keywords

African American; Asian; Hispanic; Parkinson disease; Pramipexole; Randomized clinical trials

Indexed keywords

LEVODOPA; PLACEBO; PRAMIPEXOLE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; ASTHENIA; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSKINESIA; ETHNICITY; FEMALE; GENERALIZED EDEMA; HALLUCINATION; HISPANIC; HUMAN; INHERITANCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; NEGRO; OUTCOME ASSESSMENT; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PUERTO RICO; RACE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

AFRICAN AMERICANS; AGED; ANTIPARKINSON AGENTS; ASIAN AMERICANS; BENZOTHIAZOLES; CROSS-CULTURAL COMPARISON; DOUBLE-BLIND METHOD; FEMALE; HISPANIC AMERICANS; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 34147202232     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000240943.59617.4c     Document Type: Article

References (45)

1. Franciosa JA, Taylor AL, Cohn JN, et al. African-American heart failure trial (A-HeFT): rationale, design, and methodology. J Card Fail 2002;8:128-135.
2. Wadman M. Drug targeting: is race enough? Nature 2005;435:1008-1009.
3. Rivera-Calimlim L, Reilly DK. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance. Clin Pharmacol Ther 1984;35:804-809.
4. Chaudhuri KR, Hu MT, Brooks DJ. Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK. Mov Disord 2000;15:18-23.
5. Parkinson Study Group (Kieburtz K, primary author). Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
6. Parkinson Study Group (Kieburtz K, primary author). Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA 1997;278:125-130.
7. Parkinson Study Group (Kieburtz K, primary author). Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 1996;40:99-107.
8. Parkinson Study Group (Schwid S, primary author). The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Clin Neuropharmacol 1999;22:220-225.
9. Parkinson Study Group (Schwid S, primary author). A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Neurology 2000;54:1583-1588.
10. Parkinson Study Group (Holloway R, primary author). Pramipexole vs levodopa as initial treatment for Parkinson disease. A randomized controlled trial. JAMA 2000;284:1931-1938.
11. Parkinson Study Group (Schwid S, primary author). A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 2001;56:455-462.
12. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease. Evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
13. Parkinson Study Group (Siderowf A, primary author). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 2002;59:1937-1943.
14. Parkinson Study Group (Blindauer K, primary author). A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003;60:1721-1728.
15. Parkinson Study Group (Schwid S, primary author). A randomized placebo-controlled trial of rasagiline in levodopa-treated Parkinson's disease patients with motor fluctuations (the PRESTO Study). Arch Neurol 2005;62:241-248.
16. Ogawa N, Kanazawa I, Kowa H, et al. Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up. Eur Neurol 1997;38(suppl 2):37-49.
17. Kohno Y, Takeuchi S. Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole. Nippon Yakurigaku Zasshi 2004;123(6):429-440. Article in Japanese.
18. Wong KS, Lu CS, Shan DE, et al. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. J Neurol Sci 2003;216(1):81-87.
19. Neshige R. Optimum dosage of pergolide in patients with Parkinson's disease. Rinsho Shinkeigaku 2005;45(4):328-330. Article in Japanese.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
21. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of subjects for the clinician. J Psychiatr Res 1975;12:189-198.
22. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of Neurologic Deficit. Boston, MA: Butterworth-Heinemann, 1989:285-309.
23. Welsh M, McDermott M, Holloway R, et al. Development and testing of the Parkinson's disease quality of life scale: the PDQUALIF. Mov Disord 1997;12:836. Abstract.
24. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, eds. Third Symposium on Parkinson's Disease. Edinburg: Livingston, 1969:152-157.
25. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-1022.
26. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-168.
27. Wermuth L. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neurol 1998;5:235-242.
28. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double-blind, placebo-controlled, randomized, multicentre study. J Neurol Neurosurg Psychiatry 1999;66:436-441.
29. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International pramipexole-bromocriptine study group. Neurology 1997;49:1060-1065.
30. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm Suppl 1995;45:225-230.
31. Moller JC, Oertel WH, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005;20:602-610.
32. Wong KS, Lu CS, Shan DE, et al. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease. J Neurol Sci 2003;216:81-87.
33. Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord 2003;18:1149-1156.
34. Parkinson Study Group (Holloway R, primary author). Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
35. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720-2726.
36. Rathore SS, Krumholz HM. Race, ethnic group, and clinical research. BMJ 2003;327:763-764.
37. Cox K, McGarry J. Why patients don't take part in cancer clinical trials: an overview of the literature. Eur J Cancer Care (Engl) 2003;12:114-122.
38. Bartlett C, Davey P, Dieppe P, et al. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. Heart 2003;89:327-328.
39. Peterson ED, Lytle BL, Biswas MS, et al. Willingness to participate in cardiac trials. Am J Geriatr Cardiol 2004;13:11-15.
40. Wright CE, Sisson TL, Ichhpurani AK, et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997;37:520-525.
41. Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos 2005;33:495-499.
42. Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 2004;308:2-9.
43. Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics 2003;13:581-584.
44. Shu Y, Leabman MK, Feng B, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A 2003;100:5902-5907.
45. Risch N, Burchard E, Ziv E, et al. Categorization of humans in biomedical research: genes, race, and disease. Genome Biol 2002;3:1-12.